Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

Yutaka Kawakami, Siona Eliyahu, Cynthia H. Delgado, Paul F. Robbins, Kazuyasu Sakaguchi, Ettore Appella, John R. Yannelli, Gosse J. Adema, Toru Miki, Steven A. Rosenberg

Research output: Contribution to journalArticle

807 Citations (Scopus)

Abstract

The cultured T-cell line TIL1200, established from the tumor-infiltrating lymphocytes (TILs) of a patient with advanced metastatic melanoma, recognized an antigen on most HLA-A2+ melanomas and on all HLA-A2+ cultured neonatal melanocytes in an HLA-A2 restricted manner but not on other types of tissues or cell lines tested. A cDNA encoding an antigen recognized by TIL1200 was isolated by screening an HLA-A2+ breast cancer cell line transfected with an expression cDNA library prepared from an HLA-A2+ melanoma cell line. The nucleotide and amino acid sequences of this cDNA were almost identical to the genes encoding glycoprotein gp100 or Pme117 previously registered in the GenBank. Expression of this gene was restricted to melanoma and melanocyte cell lines and retina but was not expressed on other fresh or cultured normal tissues or other types of tumor tested. The cell line transfected with this cDNA also expressed antigen recognized by the melanoma-specific antibody HMB45 that bound to gp100. A synthetic 10-amino acid peptide derived from gp100 was recognized by TIL1200 in the context of HLA-A2.1. Since the administration of TIL1200 plus interleukin 2 resulted in regression of metastatic cancer in the autologous patient, gp100 is a possible tumor rejection antigen and may be useful for the development of immunotherapies for patients with melanoma.

Original languageEnglish
Pages (from-to)6458-6462
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume91
Issue number14
Publication statusPublished - 1994 Jul 5
Externally publishedYes

Fingerprint

Melanoma-Specific Antigens
Tumor-Infiltrating Lymphocytes
Forensic Anthropology
HLA-A2 Antigen
Cell Line
Melanoma
Neoplasms
Complementary DNA
Melanocytes
Nucleic Acid Databases
Neoplasm Antigens
Gene Library
Immunotherapy
Interleukin-2
Retina
Amino Acid Sequence
Cultured Cells
Glycoproteins
Nucleotides
Breast Neoplasms

Keywords

  • Expression cloning
  • Gp100/HLA-A2.1
  • Immunotherapy
  • Tumor antigen

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., ... Rosenberg, S. A. (1994). Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proceedings of the National Academy of Sciences of the United States of America, 91(14), 6458-6462.

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. / Kawakami, Yutaka; Eliyahu, Siona; Delgado, Cynthia H.; Robbins, Paul F.; Sakaguchi, Kazuyasu; Appella, Ettore; Yannelli, John R.; Adema, Gosse J.; Miki, Toru; Rosenberg, Steven A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 91, No. 14, 05.07.1994, p. 6458-6462.

Research output: Contribution to journalArticle

Kawakami, Y, Eliyahu, S, Delgado, CH, Robbins, PF, Sakaguchi, K, Appella, E, Yannelli, JR, Adema, GJ, Miki, T & Rosenberg, SA 1994, 'Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection', Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 14, pp. 6458-6462.
Kawakami, Yutaka ; Eliyahu, Siona ; Delgado, Cynthia H. ; Robbins, Paul F. ; Sakaguchi, Kazuyasu ; Appella, Ettore ; Yannelli, John R. ; Adema, Gosse J. ; Miki, Toru ; Rosenberg, Steven A. / Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. In: Proceedings of the National Academy of Sciences of the United States of America. 1994 ; Vol. 91, No. 14. pp. 6458-6462.
@article{3127eaa8608c42e1b41353bc96c60e9d,
title = "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection",
abstract = "The cultured T-cell line TIL1200, established from the tumor-infiltrating lymphocytes (TILs) of a patient with advanced metastatic melanoma, recognized an antigen on most HLA-A2+ melanomas and on all HLA-A2+ cultured neonatal melanocytes in an HLA-A2 restricted manner but not on other types of tissues or cell lines tested. A cDNA encoding an antigen recognized by TIL1200 was isolated by screening an HLA-A2+ breast cancer cell line transfected with an expression cDNA library prepared from an HLA-A2+ melanoma cell line. The nucleotide and amino acid sequences of this cDNA were almost identical to the genes encoding glycoprotein gp100 or Pme117 previously registered in the GenBank. Expression of this gene was restricted to melanoma and melanocyte cell lines and retina but was not expressed on other fresh or cultured normal tissues or other types of tumor tested. The cell line transfected with this cDNA also expressed antigen recognized by the melanoma-specific antibody HMB45 that bound to gp100. A synthetic 10-amino acid peptide derived from gp100 was recognized by TIL1200 in the context of HLA-A2.1. Since the administration of TIL1200 plus interleukin 2 resulted in regression of metastatic cancer in the autologous patient, gp100 is a possible tumor rejection antigen and may be useful for the development of immunotherapies for patients with melanoma.",
keywords = "Expression cloning, Gp100/HLA-A2.1, Immunotherapy, Tumor antigen",
author = "Yutaka Kawakami and Siona Eliyahu and Delgado, {Cynthia H.} and Robbins, {Paul F.} and Kazuyasu Sakaguchi and Ettore Appella and Yannelli, {John R.} and Adema, {Gosse J.} and Toru Miki and Rosenberg, {Steven A.}",
year = "1994",
month = "7",
day = "5",
language = "English",
volume = "91",
pages = "6458--6462",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "14",

}

TY - JOUR

T1 - Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

AU - Kawakami, Yutaka

AU - Eliyahu, Siona

AU - Delgado, Cynthia H.

AU - Robbins, Paul F.

AU - Sakaguchi, Kazuyasu

AU - Appella, Ettore

AU - Yannelli, John R.

AU - Adema, Gosse J.

AU - Miki, Toru

AU - Rosenberg, Steven A.

PY - 1994/7/5

Y1 - 1994/7/5

N2 - The cultured T-cell line TIL1200, established from the tumor-infiltrating lymphocytes (TILs) of a patient with advanced metastatic melanoma, recognized an antigen on most HLA-A2+ melanomas and on all HLA-A2+ cultured neonatal melanocytes in an HLA-A2 restricted manner but not on other types of tissues or cell lines tested. A cDNA encoding an antigen recognized by TIL1200 was isolated by screening an HLA-A2+ breast cancer cell line transfected with an expression cDNA library prepared from an HLA-A2+ melanoma cell line. The nucleotide and amino acid sequences of this cDNA were almost identical to the genes encoding glycoprotein gp100 or Pme117 previously registered in the GenBank. Expression of this gene was restricted to melanoma and melanocyte cell lines and retina but was not expressed on other fresh or cultured normal tissues or other types of tumor tested. The cell line transfected with this cDNA also expressed antigen recognized by the melanoma-specific antibody HMB45 that bound to gp100. A synthetic 10-amino acid peptide derived from gp100 was recognized by TIL1200 in the context of HLA-A2.1. Since the administration of TIL1200 plus interleukin 2 resulted in regression of metastatic cancer in the autologous patient, gp100 is a possible tumor rejection antigen and may be useful for the development of immunotherapies for patients with melanoma.

AB - The cultured T-cell line TIL1200, established from the tumor-infiltrating lymphocytes (TILs) of a patient with advanced metastatic melanoma, recognized an antigen on most HLA-A2+ melanomas and on all HLA-A2+ cultured neonatal melanocytes in an HLA-A2 restricted manner but not on other types of tissues or cell lines tested. A cDNA encoding an antigen recognized by TIL1200 was isolated by screening an HLA-A2+ breast cancer cell line transfected with an expression cDNA library prepared from an HLA-A2+ melanoma cell line. The nucleotide and amino acid sequences of this cDNA were almost identical to the genes encoding glycoprotein gp100 or Pme117 previously registered in the GenBank. Expression of this gene was restricted to melanoma and melanocyte cell lines and retina but was not expressed on other fresh or cultured normal tissues or other types of tumor tested. The cell line transfected with this cDNA also expressed antigen recognized by the melanoma-specific antibody HMB45 that bound to gp100. A synthetic 10-amino acid peptide derived from gp100 was recognized by TIL1200 in the context of HLA-A2.1. Since the administration of TIL1200 plus interleukin 2 resulted in regression of metastatic cancer in the autologous patient, gp100 is a possible tumor rejection antigen and may be useful for the development of immunotherapies for patients with melanoma.

KW - Expression cloning

KW - Gp100/HLA-A2.1

KW - Immunotherapy

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=0028298174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028298174&partnerID=8YFLogxK

M3 - Article

C2 - 8022805

AN - SCOPUS:0028298174

VL - 91

SP - 6458

EP - 6462

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 14

ER -